Krempa David, CBO, reported a transaction classified as exercise at Eton Pharmaceuticals, Inc. involving 25000.000000 shares for an estimated $34500.00. Reported holdings after the transaction were 50249.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
Chief Business Officer
The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at…
The shares were sold in multiple trades at prices ranging from $33.68 to $34.66. The price reported above reflects the weighted average sales price.
The shares were sold in multiple trades at prices ranging from $31.27 to $32.16. The price reported above reflects the weighted average sales price.
The shares subject to the option vested in 48 equal monthly installments from the date of grant (3-12-2020) until fully vested.
The shares were sold in multiple trades at prices ranging from $31.25 to $31.825. The price reported above reflects the weighted average sales price.
The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments.
The shares were sold in multiple trades at prices ranging from $32.67 to $33.65. The price reported above reflects the weighted average sales price.
The shares subject to option vested annually from the date of grant (8-7-2017) in four equal installments.
0 other filings
0 recent txs